Engagement Opportunity Target institutional partnerships and government grant programs around regenerative medicine and organ replacement, leveraging IVIVA's Phase 2 KidneyX award and focus on bioartificial kidneys to position for collaborative funding, co-development, or pilot programs with large health systems.

Strategic Partnerships Position IVIVA as a collaboration target for major medtech and biotech players in kidney care, enabling joint development of tissue engineering, 3D printing, and stem cell platforms that complement existing dialysis and transplant ecosystems.

Innovation Narrative Highlight the company’s use of 3D additive manufacturing and biomimetic platforms to differentiate from traditional therapies, offering a compelling story for grant funding, corporate venture, and influencer-led outreach to nephrology networks.

Market Readiness Leverage the early-stage revenue and product development status to pursue pilot studies with hospital networks, kidney care centers, and organ transplant programs that are exploring regenerative solutions and reduced donor organ shortages.

Talent & Capability Capitalize on the growing team and research orientation by proposing sponsored research partnerships, clinical advisory boards, and talent placement deals with larger biotech companies seeking to accelerate regenerative medicine pipelines.